Abraxane
paclitaxel
Table of contents
Overview
This is a summary of the European Public Assessment Report (EPAR) for Abraxane. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Abraxane.
Authorisation details
Product details | |
---|---|
Name |
Abraxane
|
Agency product number |
EMEA/H/C/000778
|
Active substance |
paclitaxel
|
International non-proprietary name (INN) or common name |
paclitaxel
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
L01CD01
|
Publication details | |
---|---|
Marketing-authorisation holder |
Bristol-Myers Squibb Pharma EEIG
|
Revision |
29
|
Date of issue of marketing authorisation valid throughout the European Union |
11/01/2008
|
Contact address |
Plaza 254 |
Product information
13/09/2021 Abraxane - EMEA/H/C/000778 - IAIN/0109
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.
Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
Assessment history
News
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 January 201523/01/2015
-
22/11/2013
-
22/11/2013